期刊文献+

激发型抗CD_(40)单克隆抗体对CD_(40)^+B细胞恶性肿瘤的生长抑制和促凋亡作用 被引量:5

Anti-CD_(40) McAb induces CD_(40)^+ malignant B cell proliferation arrest and apoptosis
原文传递
导出
摘要 目的 研究CD40 抗原在恶性B淋巴细胞肿瘤中的表达及其CD40 抗原激发所致的生物学效应。方法 将激发型CD40 单克隆抗体 (单抗 ) 5C11加入肿瘤细胞的体外培养体系 ,采用细胞计数、流式细胞仪分析等方法分析单抗 5C11对不同肿瘤细胞株的作用。结果  5C11能引起CD40 表达强阳性的多发性骨髓瘤 (MM)细胞XG2发生同型聚集 ,抑制其生长并介导细胞凋亡 ;5C11可引起CD40+ 的恶性B淋巴瘤细胞株Daudi发生同型聚集 ,抑制其生长并使细胞发生G2 M期阻滞 ,但并不介导细胞凋亡。结论 激发型CD40 单抗通过诱导恶性B淋巴瘤细胞的凋亡或使G2 M期细胞阻滞 。 Objective To study the expression of CD 40 molecule and the biological effects mediated by CD 40 molecules on malignant B cells. Methods Agonistic anti human CD 40 monoclonal antibody (5C11) was added to the cell culture system. Cell counting, PI staining, Annexin V staining and flow cytometric analysis were used to study the biological effects of 5C11 on malignant B cell lines. Results 5C11 induced homotypic aggregation, proliferation arrest and apoptosis in the multiple myeloma cell line XG2 highly expressed CD 40 . 5C11 induced B lymphoma cell line Daudi homotypic aggregation and proliferation arrest but no apoptosis. Conclusion 5C11 can inhibit proliferation of malignant B cells by inducing apoptosis or arresting the cells at G 2/M interphase.
出处 《中华血液学杂志》 CSCD 北大核心 2000年第5期237-239,共3页 Chinese Journal of Hematology
基金 杰出人才基金! ( 3 962 5 0 2 4) 国家自然科学基金青年基金! ( 3 960 0 0 5 6)
关键词 CD40抗原 单克隆抗体 多发性骨髓瘤 细胞凋亡 Antigen CD 40 Monoclonal antibody Multiple myeloma Lymphoma B cell Cell growth inhibition Apoptosis
  • 相关文献

参考文献9

  • 1周照华,中国免疫学杂志,1999年,15卷,529页
  • 2姜泊,分子生物学常用实验方法,1998年,5665页
  • 3Hostager B S,J Immunol,1996年,157卷,1047页
  • 4Alex W T,Blood,1994年,84卷,3026页
  • 5Funakoshi S,Blood,1994年,83卷,2787页
  • 6Zhang X G,Blood,1994年,83卷,3654页
  • 7Jabara H H,J Experiment Med,1990年,172卷,1861页
  • 8Jackson N,Clin Exp Immunol,1988年,72卷,351页
  • 9Ling N R,Leucocytetyping Ⅲ,1987年,302页

同被引文献45

  • 1瞿秋霞,陈永井,葛彦,王勤,陈成,杨明峰,张学光.抗人CD40人-鼠嵌合抗体的构建及其表达[J].细胞与分子免疫学杂志,2006,22(2):189-192. 被引量:10
  • 2周桓,席泓,马倩茹,陈成,张烽,张学光,顾宗江.激发型CD40单克隆抗体联合特异性细胞毒T淋巴细胞对B细胞淋巴瘤的免疫治疗作用[J].中华肿瘤杂志,2007,29(3):181-185. 被引量:1
  • 3Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer[ J]. Cancer Gene Ther, 2003, 10( 1 ) : 1 -13.
  • 4Tai YT, Li X, Tong X, et al. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma [J]. Cancer Res, 2005, 65(13): 5898-5906.
  • 5Kelley SK, Gelzleichter T, Xie D, et al. Preclinieal pharmacokineties, pharmaeodynamies, and acitivity of a humanized anti- CD40antibody ( SGN40 ) in rodents and non-human primates [ J ]. British J Pharmaco, 2006, 148(8) : 1116 - 1123.
  • 6Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870, 893, a novel CD40 agonist monoclonal antibody [J]. J Clin Oncol, 2007, 25 : 876 - 883.
  • 7Hurwitz AA, Kwon ED, van Elsas A. Cosfimulatory wars: the tumor menace[J]. Curr opin Immunol, 2000, 12:589 -596.
  • 8Jakobson E, Jonsson G, Bjorck P, et al. Stimulation of CD40 in human bladder carcinoma cells inhibits anti-Fas/APO-I( CD95 ) induced apeptosis[ J]. Cancer, 1998, 77: 849- 853.
  • 9Pirozzi G, Lombarl V, Zanzi D, et al. CD40 expresed on human melanoma cells mediates T-cell costimulation and tumor cell growth [ J ]. Immunol, 2000, 12:757-795.
  • 10Costello RT, Gastaut JA, Olive D. What is the real role of CD40 in cancer immunotherapy[J].Immunol Today, 1999, 20:488 -493.

引证文献5

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部